Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Dynavax Technologies Corp (NASDAQ:DVAX)

5.70
Delayed Data
As of May 26
 +0.15 / +2.70%
Today’s Change
3.20
Today|||52-Week Range
17.50
+44.30%
Year-to-Date
Biotech Needs a Shot in the Arm
May 26 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close5.55
Today’s open5.75
Day’s range5.55 - 5.79
Volume1,131,272
Average volume (3 months)1,143,519
Market cap$278.1M
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)+10.15%
Earnings growth (this year)+38.93%
Earnings growth (next 5 years)--
Revenue growth (last year)+172.67%
P/E ratioNM
Price/Sales13.77
Price/Book2.47

Competitors

 Today’s
change
Today’s
% change
MTNBMatinas BioPharma Ho...-0.03-0.99%
NBRVNabriva Therapeutics...-0.09-0.89%
TTPHTetraphase Pharmaceu...-0.11-1.52%
COLLCollegium Pharmaceut...-0.35-3.83%
Data as of 4:02pm ET, 05/26/2017

Financials

Next reporting dateJuly 26, 2017
EPS forecast (this quarter)-$0.45
Annual revenue (last year)$11.0M
Annual profit (last year)-$112.4M
Net profit margin-1,018.24%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Eddie J. Gray
Senior Vice President-Operations &
Quality
David F. Novack
Corporate headquarters
Berkeley, California

Forecasts